Literature DB >> 30145695

Elevated expression of p53 in early colon polyps in a pig model of human familial adenomatous polyposis.

Krzysztof Flisikowski1, Marek Switonski2, Agata Sikorska3, Tatiana Flisikowska4, Monika Stachowiak3, Alexander Kind4, Angelika Schnieke4.   

Abstract

Familial adenomatous polyposis (FAP) is a hereditary predisposition to formation of colon polyps that can progress to colorectal cancer (CRC). The severity of polyposis varies substantially within families bearing the same germline mutation in the adenomatous polyposis coli (APC) tumour suppressor gene. The progressive step-wise accumulation of genetic events in tumour suppressor genes and oncogenes leads to oncogenic transformation, with driver alterations in the tumour protein p53 (TP53) gene playing a key role in advanced stage CRC. We analysed groups of pigs carrying a truncating mutation in APC (APC1311/+; orthologous to human APC1309/+) to study the influence of TP53 polymorphisms and expression on the frequency of polyp formation and polyp progression in early-stage FAP. Five generations of APC1311/+ pigs were examined by colonoscopy for polyposis severity and development. A total of 19 polymorphisms were found in 5'-flanking, coding, and 3' untranslated regions of TP53. The distribution of TP53 genotypes did not differ between APC1311/+ pigs with low (LP) and high (HP) number of colon polyps. p53 mRNA expression was analysed in distally located normal mucosa samples of wild-type pigs, APC1311/+ LP and HP pigs, and also in distally located polyp samples histologically classified as low-grade (LG-IEN) and high-grade intraepithelial dysplastic (HG-IEN) from APC1311/+ pigs. p53 mRNA expression was found to be significantly elevated in HG-IEN compared to LG-IEN samples (p = 0.012), suggesting a role for p53 in the early precancerous stages of polyp development.

Entities:  

Keywords:  Colorectal cancer; Familial adenomatous polyposis; Large animal model; Pig; TP53

Mesh:

Substances:

Year:  2018        PMID: 30145695     DOI: 10.1007/s13353-018-0461-6

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   3.240


  32 in total

1.  The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Authors:  Stephen B Edge; Carolyn C Compton
Journal:  Ann Surg Oncol       Date:  2010-06       Impact factor: 5.344

Review 2.  Genomic era diagnosis and management of hereditary and sporadic colon cancer.

Authors:  Edward David Esplin; Michael Paul Snyder
Journal:  World J Clin Oncol       Date:  2014-12-10

3.  Explaining variation in familial adenomatous polyposis: relationship between genotype and phenotype and evidence for modifier genes.

Authors:  M D Crabtree; I P M Tomlinson; S V Hodgson; K Neale; R K S Phillips; R S Houlston
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 4.  Targeting mutant p53 for efficient cancer therapy.

Authors:  Vladimir J N Bykov; Sofi E Eriksson; Julie Bianchi; Klas G Wiman
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

5.  Global patterns and trends in colorectal cancer incidence and mortality.

Authors:  Melina Arnold; Mónica S Sierra; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  Gut       Date:  2016-01-27       Impact factor: 23.059

6.  Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation.

Authors:  N el-Mahdani; J C Vaillant; M Guiguet; S Prévot; V Bertrand; C Bernard; R Parc; G Béréziat; B Hermelin
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  The association of p53 expression levels with clinicopathological features and prognosis of patients with colon cancer following surgery.

Authors:  Da-Zhong Cao; Xi-Long Ou; Ting Yu
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

8.  Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.

Authors:  María Abáigar; Cristina Robledo; Rocío Benito; Fernando Ramos; María Díez-Campelo; Lourdes Hermosín; Javier Sánchez-Del-Real; Jose M Alonso; Rebeca Cuello; Marta Megido; Juan N Rodríguez; Guillermo Martín-Núñez; Carlos Aguilar; Manuel Vargas; Ana A Martín; Juan L García; Alexander Kohlmann; M Consuelo Del Cañizo; Jesús M Hernández-Rivas
Journal:  PLoS One       Date:  2016-10-14       Impact factor: 3.240

Review 9.  Tumor suppressor genes in familial adenomatous polyposis.

Authors:  Nahal Eshghifar; Naser Farrokhi; Tahereh Naji; Mohammadreza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2017

10.  Computational screening and molecular dynamic simulation of breast cancer associated deleterious non-synonymous single nucleotide polymorphisms in TP53 gene.

Authors:  Kumaraswamy Naidu Chitrala; Suneetha Yeguvapalli
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

View more
  4 in total

Review 1.  Use of Translational, Genetically Modified Porcine Models to Ultimately Improve Intestinal Disease Treatment.

Authors:  Cecilia R Schaaf; Liara M Gonzalez
Journal:  Front Vet Sci       Date:  2022-05-20

2.  Efficacy and Safety of a Novel Submucosal Injection Solution for Resection of Gastrointestinal Lesions.

Authors:  Cristina Moles-Aranda; Raquel González-Pérez; Francisco Javier Gallego-Rojo; Olga Martínez-Augustin; Beatriz Clares-Naveros; Fermín Sánchez de Medina; José Antonio Morales-Molina
Journal:  J Clin Med       Date:  2020-04-18       Impact factor: 4.241

3.  Anti-Colorectal Cancer Mechanisms of Formononetin Identified by Network Pharmacological Approach.

Authors:  Lei Zhang; Yizhen Gong; Shuai Wang; Feng Gao
Journal:  Med Sci Monit       Date:  2019-10-14

4.  Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin.

Authors:  Christoph Roser; Csaba Tóth; Marcus Renner; Esther Herpel; Peter Schirmacher
Journal:  Cell Commun Signal       Date:  2021-02-12       Impact factor: 5.712

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.